Qiagen NV
(WBO:QGE2)
€
40.8
-0.54 (-1.31%)
Market Cap: 9.01 Bil
Enterprise Value: 9.48 Bil
PE Ratio: 137.61
PB Ratio: 2.86
GF Score: 87/100 
Qiagen NV at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023 / 04:20PM GMT
Release Date Price:
€44.01
(+0.57%)
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst
All right. Welcome, everybody. Good morning. I'm Matt Sykes, the Life Sciences Tools and Diagnostics analyst at Goldman Sachs. And I have a pleasure to welcome Thierry Bernard, the CEO of QIAGEN here today. Thierry, thank you very much for being here.
Thierry Bernard
Qiagen N.V. - CEO, MD & Member of Management Board
Thanks for having us.
Questions & Answers
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst
And maybe why don't we just start out, let you kind of set the stage a little bit. Last quarter, you once again exceeded expectations for net sales growth and EPS in the quarter. Maybe walk us through some of the key accomplishments and any expectations you have over the course of this year?
Thierry Bernard
Qiagen N.V. - CEO, MD & Member of Management Board
So first of all, good morning, everybody, and thanks for your
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers